Overview

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX
Phase:
Phase 1
Details
Lead Sponsor:
Medy-Tox
Treatments:
Botulinum Toxins, Type A